Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy

Area of Science:

• Neuroimmunology
• Neuropathology
• Clinical Neurology

Background:

• Multiple sclerosis (MS) is a chronic central nervous system inflammatory demyelinating disease impacting millions globally.
• Existing disease-modifying therapies (DMTs) provide limited long-term efficacy, necessitating novel treatment strategies.
• The autoimmune hypothesis, underpinning current DMT development, is increasingly challenged by new neuropathological findings.

Purpose of the Study:

• To evaluate the potential long-term efficacy of new-generation DMTs for multiple sclerosis.
• To critically assess the prevailing autoimmune hypothesis of MS pathogenesis.
• To explore alternative therapeutic targets based on emerging evidence of primary oligodendrogliopathy.

Main Methods:

• Review of current literature on MS pathogenesis and therapeutic strategies.
• Analysis of preliminary data on new-generation DMTs targeting immune pathways.
• Examination of recent neuropathological studies challenging the autoimmune model of MS.

Main Results:

• New DMTs may reduce relapses in early MS, but long-term outcomes are unproven.
• Evidence suggests MS long-term disability progression is independent of initial relapse frequency.
• Emerging research indicates MS may be a primary oligodendrogliopathy, with inflammation as a secondary event.

Conclusions:

• The long-term benefits of current new-generation DMTs for MS remain uncertain.
• Reconsidering the fundamental pathogenesis of MS is crucial for developing more effective, disease-specific treatments.
• Future therapeutic strategies may need to shift focus from solely targeting inflammation to addressing primary myelin repair and neuroprotection.